FCAR抗体,Rabbit Polyclonal FCAR Antibody
  • FCAR抗体,Rabbit Polyclonal FCAR Antibody
  • FCAR抗体,Rabbit Polyclonal FCAR Antibody
  • FCAR抗体,Rabbit Polyclonal FCAR Antibody

FCAR抗体

价格 询价
包装 20μl 50μl 100μl
最小起订量 1μl
发货地 湖北
更新日期 2025-05-14
QQ交谈 微信洽谈

产品详情

中文名称:FCAR抗体英文名称:Rabbit Polyclonal FCAR Antibody
品牌: 艾普蒂产地: 武汉
保存条件: Stored at -20°C for 4067 year. Avoid repeated freeze / thaw cycles.产品类别: 抗体
重组: 应用: WB: IHC-P: IHC-F: ICC/IF: IP:FC:ChIP: ELISA
种属反应性: Human,Mouse,Rat 宿主: Rabbit
偶联物: 靶点: FCAR
2025-05-14 FCAR抗体 Rabbit Polyclonal FCAR Antibody 20μl/RMB;50μl/RMB;100μl/RMB 艾普蒂 武汉 Stored at -20°C for 4067 year. Avoid repeated freeze / thaw cycles. 抗体

验证与应用

应用及物种
WB咨询技术 Human,Mouse,Rat
IF咨询技术 Human,Mouse,Rat
IHC1/25-1/100 Human,Mouse,Rat
ICC技术咨询 Human,Mouse,Rat
FCM咨询技术 Human,Mouse,Rat
Elisa1/2000-1/5000 Human,Mouse,Rat
   

产品详情

AliasesCD89
WB Predicted band size32 kDa
Host/IsotypeRabbit IgG
Antibody TypePrimary antibody
StorageStore at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.
Species ReactivityHuman
ImmunogenFusion protein of human FCAR
FormulationPurified antibody in PBS with 0.05% sodium azide and 50% glycerol.

+ +

  •  

     

       Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: 293T cells, Primary antibody: P08323(FCAR Antibody) at dilution 1/550, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 10 seconds    


  •  

     

       The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P08323(FCAR Antibody) at dilution 1/20. (Original magnification: ×200)    


  •  

     

       The image is immunohistochemistry of paraffin-embedded Human prostate cancer tissue using P08323(FCAR Antibody) at dilution 1/20. (Original magnification: ×200)    


           

参考文献

以下是3篇与FCAR(Fcα受体)抗体相关的文献示例,包含标题、作者及摘要概述:

---

1. **标题**:*Targeting FCAR in IgA-mediated autoimmune diseases: mechanisms and therapeutic potential*

**作者**:Leusen JH, et al.

**摘要**:探讨FCAR(FcαRI/CD89)在IgA介导的自身免疫性疾病(如IgA肾病)中的作用,分析针对FCAR的单克隆抗体通过阻断IgA-FCAR信号通路减轻炎症反应的机制。

---

2. **标题**:*Structural insights into FCAR antibody binding and its implications for immunotherapy*

**作者**:Smith AB, et al.

**摘要**:通过X射线晶体学解析FCAR与其单克隆抗体的复合物结构,揭示抗体结合表位及构象变化,为设计靶向FCAR的免疫疗法(如癌症或感染性疾病)提供理论依据。

---

3. **标题**:*FCAR-directed bispecific antibodies enhance neutrophil phagocytosis in bacterial infections*

**作者**:van Egmond M, et al.

**摘要**:开发靶向FCAR和细菌表面抗原的双特异性抗体,证实其可增强中性粒细胞的吞噬作用,显著提高小鼠模型中耐药性肺炎链球菌感染的清除效率。

---

**备注**:以上文献为示例,实际引用时需核实具体文章是否存在及细节准确性。建议通过PubMed或Google Scholar以关键词“FCAR antibody”“FcαR therapeutic”等检索最新研究。

       

背景信息

Fc alpha receptor (FCAR), also known as CD89. is a transmembrane protein belonging to the immunoglobulin superfamily. It primarily binds the Fc region of immunoglobulin A (IgA), playing a pivotal role in IgA-mediated immune responses. Expressed on myeloid cells like neutrophils, monocytes, and macrophages, FCAR facilitates immune functions such as phagocytosis, antigen presentation, and inflammatory mediator release upon IgA complex engagement. Its structure includes extracellular Ig-like domains for ligand binding, a transmembrane segment, and a cytoplasmic tail involved in intracellular signaling, often mediated through associated adaptor proteins like FcRγ.

FCAR is critical in bridging innate and adaptive immunity by regulating IgA-related pathogen clearance and immune complex handling. Dysregulation of FCAR signaling has been implicated in autoimmune disorders (e.g., IgA nephropathy) and cancers, where aberrant IgA interactions may drive inflammation or immune evasion. Therapeutic antibodies targeting FCAR are being explored to modulate immune activity, either by blocking pathogenic IgA binding or enhancing effector functions in malignancies. Recent research also highlights its potential as a biomarker for inflammatory diseases. Despite progress, FCAR's precise signaling cascades and tissue-specific roles remain areas of active investigation, underscoring its therapeutic and diagnostic relevance in IgA-linked pathologies.

       
关键字: FCAR抗体;FCAR;FCAR Antibody;

公司简介

湖北瑞和宁生物科技有限公司研究创新能力, 拥有完整、科学、质量管理体系。并不断致力于技术创新,产品创新和管理创新,赢得了国内外广大用户的信任。
成立日期 2024-06-24 (2年) 注册资本 50万(元)
员工人数 1-10人 年营业额 ¥ 100万以内
主营行业 中间体,化学试剂 经营模式 贸易,工厂,试剂,定制,服务
  • 湖北瑞和宁生物科技有限公司
VIP 1年
  • 公司成立:2年
  • 注册资本:50万(元)
  • 企业类型:有限责任公司(自然人投资或控股)
  • 主营产品:中间体。试剂
  • 公司地址:江汉区
询盘

店内推荐

FCAR抗体相关厂家报价

产品名称 价格   公司名称 报价日期
¥3104
VIP5年
上海博尔森生物科技有限公司
2025-11-17
¥1600.00
VIP10年
北京索莱宝科技有限公司
2025-11-17
¥1138
VIP4年
上海沪震实业有限公司
2025-11-17
¥1280
湖北艾普蒂生物工程有限公司
2025-06-04
内容声明:
以上所展示的信息由商家自行提供,内容的真实性、准确性和合法性由发布商家负责。 商家发布价格指该商品的参考价格,并非原价,该价格可能随着市场变化,或是由于您购买数量不同或所选规格不同而发生变化。最终成交价格,请咨询商家,以实际成交价格为准。请意识到互联网交易中的风险是客观存在的
主页 | 企业会员服务 | 广告业务 | 联系我们 | 旧版入口 | 中文MSDS | CAS Index | 常用化学品CAS列表 | 化工产品目录 | 新产品列表 |投诉中心
Copyright © 2008 ChemicalBook 京ICP备07040585号  京公海网安备110108000080号  All rights reserved.